Fahrleitner A, Prenner G, Leb G, Tscheliessnigg K H, Piswanger-Sölkner C, Obermayer-Pietsch B, Portugaller H R, Berghold A, Dobnig H
Department of Internal Medicine, Division of Endocrinology and Metabolism, Karl Franzens University, Auenbruggerplatz 15, A-8036 Graz, Austria.
Bone. 2003 Jan;32(1):96-106. doi: 10.1016/s8756-3282(02)00926-2.
Osteoprotegerin (OPG) is an antiresorptive cytokine and a key regulator of osteoclastogenesis and activity. Since OPG is downregulated by glucocorticoids and cyclosporine A in vitro we examined whether immunosuppressive therapy would play a role in the development of transplantation osteoporosis. We enrolled 57 cardiac transplant recipients (median time since transplantation, 3.2 years (1.1-11.5 years)) in this cross-sectional study. Standardized spinal X-rays as well as hip bone density measurements were performed in all patients. Serum OPG was determined using a commercially available ELISA. Vertebral fractures were present in 56% of the patients. Bone densities of all femoral neck subregions were correlated to serum OPG concentrations (r values between 0.40 and 0.48, all P < 0.005). Multiple regression analysis revealed OPG levels to be independently correlated to femoral neck Z scores (r = 0.49, P = 0.002). After adjustment for age, BMI, neck Z score, renal function, and months since transplantation, serum OPG was the only significant predictor of prevalent vertebral fractures (P = 0.001). In a separate 6-month prospective study of 14 heart transplant recipients receiving calcium and vitamin D serum OPG levels fell by 41% (P = 0.0004) after 3 months and 47% (P = 0.0001) after 6 months following cardiac transplantation. Bone loss at the lumbar spine and femoral neck after 6 months was correlated to the decrease in serum OPG at 6 months (r = 0.82, P < 0.0001, and r = 0.60, P = 0.02, respectively) as well as 3 months after cardiac transplantation (r = 0.65, P = 0.01, and r = 0.69, P = 0.006, respectively). Serum OPG alone accounted for 67% of the variance of lumbar spine bone density changes over the first 6 months posttransplantation. We conclude that serum OPG levels decline consistently in all patients following initiation of immunosuppressive therapy and are independently correlated with changes in bone density. We hypothesize that OPG plays a major role in the development of transplantation osteoporosis.
骨保护素(OPG)是一种抗吸收细胞因子,也是破骨细胞生成和活性的关键调节因子。由于在体外糖皮质激素和环孢素A可下调OPG,我们研究了免疫抑制治疗是否会在移植后骨质疏松的发生中起作用。在这项横断面研究中,我们纳入了57例心脏移植受者(移植后的中位时间为3.2年(1.1 - 11.5年))。对所有患者进行了标准化的脊柱X线检查以及髋部骨密度测量。使用市售酶联免疫吸附测定法(ELISA)测定血清OPG。56%的患者存在椎体骨折。所有股骨颈亚区域的骨密度与血清OPG浓度相关(r值在0.40至0.48之间,所有P < 0.005)。多元回归分析显示OPG水平与股骨颈Z评分独立相关(r = 0.49,P = 0.002)。在调整年龄、体重指数、颈Z评分、肾功能和移植后的月数后,血清OPG是椎体骨折患病率的唯一显著预测因子(P = 0.001)。在一项针对14例接受钙和维生素D的心脏移植受者的为期6个月的前瞻性研究中,心脏移植后3个月血清OPG水平下降了41%(P = 0.0004),6个月后下降了47%(P = 0.0001)。6个月后腰椎和股骨颈的骨质流失与6个月时血清OPG的下降相关(r分别为0.82,P < 0.0001和r = 0.60,P = 0.02),也与心脏移植后3个月时相关(r分别为0.65,P = 0.01和r = 0.69,P = 0.006)。仅血清OPG就占移植后前6个月腰椎骨密度变化方差的67%。我们得出结论,免疫抑制治疗开始后所有患者的血清OPG水平持续下降,且与骨密度变化独立相关。我们推测OPG在移植后骨质疏松的发生中起主要作用。